125 related articles for article (PubMed ID: 1607708)
1. Complement factor 9 deficiency in serum of human neonates.
Lassiter HA; Watson SW; Seifring ML; Tanner JE
J Infect Dis; 1992 Jul; 166(1):53-7. PubMed ID: 1607708
[TBL] [Abstract][Full Text] [Related]
2. Supplemental complement component C9 enhances the capacity of neonatal serum to kill multiple isolates of pathogenic Escherichia coli.
Lassiter HA; Wilson JL; Feldhoff RC; Hoffpauir JM; Klueber KM
Pediatr Res; 1994 Apr; 35(4 Pt 1):389-96. PubMed ID: 8047374
[TBL] [Abstract][Full Text] [Related]
3. Complement component C9 enhances the capacity of beta-lactam antibiotics to kill Escherichia coli in vitro and in vivo.
Jung E; Feldhoff RC; Walz BM; Drehs MM; Buchheit JQ; Lassiter HA
Am J Med Sci; 1998 May; 315(5):307-13. PubMed ID: 9587087
[TBL] [Abstract][Full Text] [Related]
4. Inefficient bacteriolysis of Escherichia coli by serum from human neonates.
Lassiter HA; Tanner JE; Miller RD
J Infect Dis; 1992 Feb; 165(2):290-8. PubMed ID: 1730895
[TBL] [Abstract][Full Text] [Related]
5. The administration of complement component C9 enhances the survival of neonatal rats with Escherichia coli sepsis.
Lassiter HA; Walz BM; Wilson JL; Jung E; Calisi CR; Goldsmith LJ; Wilson RA; Morgan BP; Feldhoff RC
Pediatr Res; 1997 Jul; 42(1):128-36. PubMed ID: 9212048
[TBL] [Abstract][Full Text] [Related]
6. Immunologic regulation of E. coli K1 by serum from neonatal rats is enhanced following intraperitoneal administration of human IgG.
Lassiter HA; Christensen RD; Parker CJ
J Infect Dis; 1989 Mar; 159(3):518-25. PubMed ID: 2644382
[TBL] [Abstract][Full Text] [Related]
7. Bactericidal activity of C9-deficient human serum.
Pramoonjago P; Kinoshita T; Hong KS; Takata-Kozono Y; Kozono H; Inagi R; Inoue K
J Immunol; 1992 Feb; 148(3):837-43. PubMed ID: 1730876
[TBL] [Abstract][Full Text] [Related]
8. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
9. The role of C9 in complement-mediated killing of Neisseria.
Harriman GR; Esser AF; Podack ER; Wunderlich AC; Braude AI; Lint TF; Curd JG
J Immunol; 1981 Dec; 127(6):2386-90. PubMed ID: 6795273
[TBL] [Abstract][Full Text] [Related]
10. A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan.
Fukumori Y; Yoshimura K; Ohnoki S; Yamaguchi H; Akagaki Y; Inai S
Int Immunol; 1989; 1(1):85-9. PubMed ID: 2487678
[TBL] [Abstract][Full Text] [Related]
11. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
12. Further studies on C9 deficiency.
Kitamura H; Nagaki K; Inai S
J Clin Lab Immunol; 1981 Jul; 6(1):7-11. PubMed ID: 7265179
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous immunoglobulin G on the deposition of immunoglobulin G and C3 onto type III group B streptococcus and Escherichia coli K1.
Lassiter HA; Robinson TW; Brown MS; Hall DC; Hill HR; Christensen RD
J Perinatol; 1996; 16(5):346-51. PubMed ID: 8915932
[TBL] [Abstract][Full Text] [Related]
14. Human complement C7 and C9 in fetal and newborn sera.
Adinolfi M; Beck SE
Arch Dis Child; 1975 Jul; 50(7):562-4. PubMed ID: 1172656
[TBL] [Abstract][Full Text] [Related]
15. Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9.
O'Hara AM; Moran AP; Würzner R; Orren A
Immunology; 2001 Mar; 102(3):365-72. PubMed ID: 11298837
[TBL] [Abstract][Full Text] [Related]
16. Multimeric C9 within C5b-9 is required for inner membrane damage to Escherichia coli J5 during complement killing.
Bloch EF; Schmetz MA; Foulds J; Hammer CH; Frank MM; Joiner KA
J Immunol; 1987 Feb; 138(3):842-8. PubMed ID: 3100618
[TBL] [Abstract][Full Text] [Related]
17. The analysis of the complement activation product SC5 b-9 is applicable in neonates in spite of their profound C9 deficiency.
Høgåsen AK; Overlie I; Hansen TW; Abrahamsen TG; Finne PH; Høgåsen K
J Perinat Med; 2000; 28(1):39-48. PubMed ID: 10765513
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody 2-2-B kills K1-positive Escherichia coli in conjunction with cord blood neutrophils and sera, but not with spinal fluid.
Cross AS; Wooldridge WH; Zollinger WD
Pediatr Res; 1984 Aug; 18(8):770-2. PubMed ID: 6382138
[TBL] [Abstract][Full Text] [Related]
19. The role of complement and antibodies in the impaired bactericidal activity of neonatal sera against gram-negative bacteria.
Jankowski S
Acta Microbiol Pol; 1995; 44(1):5-14. PubMed ID: 7660858
[TBL] [Abstract][Full Text] [Related]
20. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.
Kochi SK; Johnson RC; Dalmasso AP
J Immunol; 1991 Jun; 146(11):3964-70. PubMed ID: 2033266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
